TechMARK movers: Oxford BioMedica gains on update

14th May 2009 12:56

Shares in Oxford BioMedica are up after the gene therapy group said the new ocular collaboration with sanofi-aventis and the termination of the TroVax collaboration will have a significant positive effect on its financial results for the current year and on the medium-term outlook.Recognised revenue for 2009 is expected to be about £20m compared with £18m last year."With our enhanced cash position, we are well positioned in this challenging financial environment and I am confident that we can deliver on our other near-term strategic objectives," said chief executive John Dawson.Speciality pharmaceutical group ProStrakan said revenues were up by 40% in the first four months of the year, with rectal ointment Rectogesic and nausea prevention drug Xomolix among the treatments contributing to the rise."The strength of our performance in the first four months of 2009 reinforces our confidence in achieving our stated target of reaching breakeven in the closing months of 2009," said chief executive Wilson Totten.FTSE TechMARK - RisersRobotic Technology (RTS) 5.25p +20.00%Oxford Biomedica (OXB) 10.00p +11.11%AEA Technology (AAT) 18.75p +7.14%Innovation Group (TIG) 8.04p +4.69%Alizyme (AZM) 6.10p +3.74%ProStrakan (PSK) 79.00p +3.27%Vislink (VLK) 29.00p +2.65%ARC International (ARK) 11.50p +2.22%Ricardo Group (RCDO) 187.00p +2.19%Dialight (DIA) 130.00p +1.96%FTSE TechMARK - FallersPuricore (PURI) 11.25p -10.00%Sepura (SEPU) 43.50p -5.43%Parity Group (PTY) 13.75p -5.17%Torotrak (TRK) 28.50p -4.20%E2V Technologies (E2V) 82.00p -4.09%Emblaze (BLZ) 36.50p -3.95%Morse (MOR) 12.75p -3.77%Filtronic (FTC) 30.75p -3.15%Wolfson Microelectronics (WLF) 114.50p -2.55%Imagination Technologies (IMG) 107.25p -2.50%